CN118370871B - Preparation method of decellularized biological omentum and decellularized biological omentum prepared by same - Google Patents
Preparation method of decellularized biological omentum and decellularized biological omentum prepared by same Download PDFInfo
- Publication number
- CN118370871B CN118370871B CN202410815430.2A CN202410815430A CN118370871B CN 118370871 B CN118370871 B CN 118370871B CN 202410815430 A CN202410815430 A CN 202410815430A CN 118370871 B CN118370871 B CN 118370871B
- Authority
- CN
- China
- Prior art keywords
- decellularized
- phosphate buffer
- omentum
- liquid
- concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000002747 omentum Anatomy 0.000 title claims abstract description 67
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 239000007788 liquid Substances 0.000 claims abstract description 41
- 238000000034 method Methods 0.000 claims abstract description 26
- 230000001954 sterilising effect Effects 0.000 claims abstract description 19
- 238000005238 degreasing Methods 0.000 claims abstract description 7
- 238000004108 freeze drying Methods 0.000 claims abstract description 7
- 239000008363 phosphate buffer Substances 0.000 claims description 50
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 31
- 102000006382 Ribonucleases Human genes 0.000 claims description 28
- 108010083644 Ribonucleases Proteins 0.000 claims description 28
- 210000001519 tissue Anatomy 0.000 claims description 22
- 102000004882 Lipase Human genes 0.000 claims description 18
- 108090001060 Lipase Proteins 0.000 claims description 18
- 239000004367 Lipase Substances 0.000 claims description 18
- 235000019421 lipase Nutrition 0.000 claims description 18
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 15
- 238000001914 filtration Methods 0.000 claims description 15
- 238000005303 weighing Methods 0.000 claims description 15
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 10
- 238000005406 washing Methods 0.000 claims description 10
- 239000000243 solution Substances 0.000 claims description 9
- 239000008055 phosphate buffer solution Substances 0.000 claims description 8
- 238000002791 soaking Methods 0.000 claims description 8
- 238000004140 cleaning Methods 0.000 claims description 2
- 239000012046 mixed solvent Substances 0.000 claims description 2
- 230000010355 oscillation Effects 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 1
- 108020004414 DNA Proteins 0.000 description 14
- 102000016911 Deoxyribonucleases Human genes 0.000 description 12
- 108010053770 Deoxyribonucleases Proteins 0.000 description 12
- 239000011159 matrix material Substances 0.000 description 7
- 210000003491 skin Anatomy 0.000 description 7
- 239000012620 biological material Substances 0.000 description 6
- 238000011532 immunohistochemical staining Methods 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000008439 repair process Effects 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 229920002549 elastin Polymers 0.000 description 3
- 210000002744 extracellular matrix Anatomy 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 244000309715 mini pig Species 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 210000004876 tela submucosa Anatomy 0.000 description 3
- 230000017423 tissue regeneration Effects 0.000 description 3
- 241000486679 Antitype Species 0.000 description 2
- 102000012422 Collagen Type I Human genes 0.000 description 2
- 108010022452 Collagen Type I Proteins 0.000 description 2
- 102000004266 Collagen Type IV Human genes 0.000 description 2
- 108010042086 Collagen Type IV Proteins 0.000 description 2
- 238000007400 DNA extraction Methods 0.000 description 2
- 208000005156 Dehydration Diseases 0.000 description 2
- 102000016942 Elastin Human genes 0.000 description 2
- 108010014258 Elastin Proteins 0.000 description 2
- 108091029865 Exogenous DNA Proteins 0.000 description 2
- 102000016359 Fibronectins Human genes 0.000 description 2
- 108010067306 Fibronectins Proteins 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000282898 Sus scrofa Species 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 210000004303 peritoneum Anatomy 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108091027757 Deoxyribozyme Proteins 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 210000001691 amnion Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000004061 bleaching Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000000569 greater omentum Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000012792 lyophilization process Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 208000028241 peripheral precocious puberty Diseases 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000002278 reconstructive surgery Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000007665 sagging Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 210000003384 transverse colon Anatomy 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
- A61L27/3633—Extracellular matrix [ECM]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
- A61L27/3687—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment characterised by the use of chemical agents in the treatment, e.g. specific enzymes, detergents, capping agents, crosslinkers, anticalcification agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
- A61L27/3691—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment characterised by physical conditions of the treatment, e.g. applying a compressive force to the composition, pressure cycles, ultrasonic/sonication or microwave treatment, lyophilisation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/40—Preparation and treatment of biological tissue for implantation, e.g. decellularisation, cross-linking
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Dermatology (AREA)
- Veterinary Medicine (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Botany (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Zoology (AREA)
- Materials For Medical Uses (AREA)
Abstract
The invention discloses a preparation method of a decellularized biological omentum and the decellularized biological omentum prepared by the preparation method, which comprises the following steps: 1) Degreasing fresh large omentum tissue; 2) The fat-removed large omentum tissue is immersed in the decellularized liquid I in an oscillating way for treatment; 3) Treating the large omentum tissue treated by the decellularized liquid I in a decellularized liquid II; 4) Treating the large omentum tissue treated by the decellularized liquid II in the decellularized liquid III; 5) And (3) freeze-drying and sterilizing the large omentum tissue treated by the decellularized liquid III. The method has the advantages of simpler and more convenient operation and shorter period, and the DNA content in the decellularized omentum is lower by adopting the decellularized liquid I, II and III with specific formulas.
Description
Technical Field
The invention belongs to the technical field of biology, and particularly relates to a preparation method of a decellularized biological omentum and the decellularized biological omentum prepared by the same.
Background
The decellularized matrix biological material is a novel biological material which is prepared by performing decellularized treatment on tissues/organs by a proper method, removing cells and other antigen molecules possibly causing rejection reaction in the tissues, retaining a three-dimensional structure and functional proteins, has a biological induction function, can form specific functional tissues in vivo/in vitro, and can be used for repairing/reconstructing tissue injury. The existing cell-free biological materials with more applications are mainly heterogeneous cell-free matrixes, and raw materials of the natural biological materials mainly come from animal small intestine submucosa, bladder submucosa, stomach submucosa, pericardium, amniotic membrane, peritoneum and dermis layers.
The large omentum (greater omentum) is a peritoneal tissue connecting the greater curvature of the stomach to the transverse colon, bulging forward from between the stomach and the intestine, sagging in front of the intestine to form folds, in the form of aprons, covering the empty and ileum. The large omentum has wide sources, is highly vascularized and rich in various growth factors, and is widely used for in vivo implantation platforms of various implants at present. For example, it may be used in surgical reconstructive surgery for repair of inflammatory or defective tissue, promoting vascularization and regeneration of tissue. The acellular matrix biomaterial is widely used in the medical field, and has the ability to induce tissue regeneration compared with non-absorbable materials or conventional polymer materials, and thus is considered to be an ideal tissue repair material. However, animal-derived biological materials also present some risks, on the one hand, in that the foreign residual DNA, fat, etc. carried by them may cause an immune response after implantation into the human body, and on the other hand, in that the reagents used in the treatment process easily break the three-dimensional structure of the extracellular matrix (Extracellular matrix, ECM), so that they lose the ability to induce tissue regeneration in the body.
Aiming at the technical problems, the Chinese patent application CN104771788B discloses a tissue engineering skin based on a large omentum acellular matrix and a construction method thereof, and the construction method of the tissue engineering skin comprises the following steps: (1) Preparing a macroreticular lamina decellularized matrix scaffold material, which comprises the steps of immersing the macroreticular lamina in a buffer solution containing sodium dodecyl sulfate and DNase for decellularizing treatment; and (2) tissue engineering skin construction and culture. Tissue engineering skin obtained by the method is also provided. The large omentum decellularized matrix is rich in the blood vessel promoting growth factors, so that capillary blood vessels can be promoted to grow into the transplanted tissue engineering skin from the wound surface, the vascularization and wound surface healing of the tissue engineering skin are facilitated, and the method has important significance for clinical application of the tissue engineering skin. However, the content of exogenous DNA in the large omentum decellularized matrix prepared by the method still has room for further improvement.
In addition, chinese patent application CN116832217a also discloses an improved method for preparing decellularized biological omentum, comprising the following pretreatment: taking fresh pig omentum, and washing with PBS; decellularization and dehydration treatment: the washed large omentum is put into a freeze dryer for freeze drying, and the freeze drying procedure is as follows: -40 ℃ for 5 hours, -25 ℃ for 2 hours, -10 ℃ for 2 hours, 4 ℃ for 4 hours, 25 ℃ for 8 hours. The lyophilization process is effective in decellularizing and maximally preserving ECM components. The improved preparation method of the decellularized biological omentum has the advantages that the traditional repeated freeze thawing method is used for performing the decellularization treatment, the required period is too long, the damage to the ECM components is relatively large, the method can be replaced by a freeze-drying step, the effects of dehydrating and inactivating the cells are better, and the ECM components such as collagen and glycosaminoglycan are better reserved. However, the above-described method has room for further improvement in how to remove exogenous DNA.
Therefore, how to provide a preparation method of a decellularized biological omentum with simpler operation, shorter period and lower DNA content in the decellularized omentum is still a problem to be solved by the person skilled in the art.
Disclosure of Invention
In summary, the present invention is directed to a method for preparing a decellularized biological omentum to reduce the DNA content in the decellularized omentum. In order to achieve the above purpose, the following technical scheme is adopted:
The invention relates to a preparation method of a decellularized biological omentum, which comprises the following steps:
1) Taking fresh large omentum tissue, cleaning in phosphate buffer solution, and oscillating and soaking the cleaned tissue in degreasing solution for 12-36h (preferably 20-28 h), wherein the oscillating frequency is 150-250r/min (preferably 180-220 r/min);
2) Washing the fat-removed large omentum tissue in phosphate buffer solution, and oscillating and soaking in decellularized solution I for 6-10h (preferably 7-9 h), wherein the oscillating frequency is 100-200r/min (preferably 120-180 r/min);
3) Washing the large omentum tissue treated by the decellularized liquid I in phosphate buffer solution, and oscillating and soaking the large omentum tissue in the decellularized liquid II for 6-10h (preferably 7-9 h), wherein the oscillating frequency is 100-200r/min (preferably 120-180 r/min);
4) Washing the large omentum tissue treated by the decellularized liquid II in phosphate buffer solution, and oscillating and soaking the large omentum tissue in the decellularized liquid III for 6-10h (preferably 7-9 h), wherein the oscillating frequency is 100-200r/min (preferably 120-180 r/min);
5) Freeze-drying the large omentum tissue treated by the decellularized liquid III and then sterilizing;
Wherein, the preparation steps of the decellularized liquid are as follows:
1) Decellularized liquid I: weighing sodium dodecyl sulfate, RNase and lipase, dissolving in phosphate buffer, wherein the concentration of sodium dodecyl sulfate in the phosphate buffer is 1.5-2.5% by weight (preferably 1.8-2.2% by weight), the concentration of RNase in the phosphate buffer is 2500-3500U/L (preferably 2800-3200U/L), the concentration of lipase in the phosphate buffer is 1000-2000U/L (preferably 1200-1800U/L), the pH is 7.2-7.4, filtering and sterilizing;
2) Decellularized liquid II: weighing sodium dodecyl sulfate, RNase and lipase, dissolving in phosphate buffer, wherein the concentration of sodium dodecyl sulfate in the phosphate buffer is 0.6-1.5% by weight (preferably 0.8-1.2% by weight), the concentration of RNase in the phosphate buffer is 1500-2000U/L (preferably 1200-1800U/L), the concentration of lipase in the phosphate buffer is 500-1000U/L (preferably 600-800U/L), the pH is 7.2-7.4, filtering and sterilizing;
3) Decellularized liquid III: weighing sodium dodecyl sulfate, RNase and lipase, dissolving in phosphate buffer, wherein the concentration of sodium dodecyl sulfate in the phosphate buffer is 0.1-0.5% by weight (preferably 0.2-0.4% by weight), the concentration of RNase in the phosphate buffer is 1000-1500U/L (preferably 1100-1300U/L), the concentration of lipase in the phosphate buffer is 300-500U/L (preferably 350-450U/L), the pH is 7.2-7.4, filtering and sterilizing. It should be noted that the above-mentioned preferable amount of each component is advantageous for further reducing the DNA content in the decellularized biological omentum.
In one embodiment of the invention, the degreasing solution is a mixed solvent of methanol and isopropanol.
In a more specific embodiment, the methanol and isopropanol are present in a volume ratio of 1 to 2: 1-2.
The invention also relates to the decellularized biological net film prepared by the preparation method.
In one embodiment of the invention, the DNA content of the decellularized biological omentum is less than 12 μg/g; preferably less than 9 μg/g.
The invention has the beneficial effects that: the method has the advantages of simpler and more convenient operation and shorter period, and the DNA content in the decellularized omentum is lower by adopting the decellularized liquid I, II and III with specific formulas.
Drawings
FIG. 1 Decellularized biological omentum type I collagen immunohistochemical staining X200.
FIG. 2 Decellularized biological omentum type IV collagen immunohistochemical staining X200.
FIG. 3 immunohistochemical staining of decellularized biological omentum fibronectin X200.
FIG. 4 Decellularized biological omentum elastin immunohistochemical staining X200.
FIG. 5 DNA content detection in natural large omentum tissue and DNase decellularized and RNase decellularized biological omentump<0.01）。
Detailed Description
Example 1: decellularized treatment of large omentum of small pig origin
(1) Preparation of degreasing solution
Methanol and isopropanol are mixed according to the volume ratio of 1:1, mixing evenly;
(2) Preparation of cell-free liquid
1) Decellularized liquid I: weighing sodium dodecyl sulfate, RNase and lipase, dissolving in phosphate buffer, wherein the concentration of sodium dodecyl sulfate in the phosphate buffer is 2% by weight, the concentration of RNase in the phosphate buffer is 3000U/L, the concentration of lipase in the phosphate buffer is 1500U/L, the pH is 7.3, filtering and sterilizing;
2) Decellularized liquid II: weighing sodium dodecyl sulfate, RNase and lipase, dissolving in phosphate buffer, wherein the concentration of sodium dodecyl sulfate in the phosphate buffer is 1% by weight, the concentration of RNase in the phosphate buffer is 1800U/L, the concentration of lipase in the phosphate buffer is 750U/L, the pH is 7.3, filtering and sterilizing;
3) Decellularized liquid III: weighing sodium dodecyl sulfate, RNase and lipase, dissolving in phosphate buffer, wherein the concentration of sodium dodecyl sulfate in the phosphate buffer is 0.3% by weight, the concentration of RNase in the phosphate buffer is 1200U/L, the concentration of lipase in the phosphate buffer is 400U/L, the pH is 7.3, filtering and sterilizing;
(3) Large omentum decellularization treatment:
fresh minipig peritoneum macroreticular tissue (purchased from slaughterhouse) (1 kg) was taken and washed 3 times in 1L PBS (Solarbio). The cleaned tissue is immersed in 2L degreasing solution for 24h under shaking with the shaking frequency of 200r/min. Subsequently, the fat-removed large omentum tissue was washed 3 times in PBS and treated by shaking immersion in decellularized liquid I (1L) for 8h at a shaking frequency of 150r/min. Subsequently, the large omentum tissue treated by the decellularized liquid I is washed 3 times in PBS, and is immersed in the decellularized liquid II (1L) for 8 hours in an oscillating way, and the oscillating frequency is 150r/min. Subsequently, the large omentum tissue treated by the decellularized liquid II is washed 3 times in PBS and is immersed in the decellularized liquid III (1L) for 8 hours in an oscillating way, and the oscillating frequency is 150r/min. Finally, the large omentum tissue treated by the decellularized liquid III is subjected to freeze drying (GIPP-100 FDB, shanghai secondary spectrum) and then irradiation sterilization (delivered golden bright radiation company Co., ltd.) and is preserved at normal temperature.
EXAMPLE 2 immunohistochemical staining and identification of decellularized biological omentum
The decellularized biological omentum prepared in example 1 was fixed with 4% paraformaldehyde solution, concentration-graded alcohol dehydrated, paraffin embedded, and sections with a thickness of 4 mm were prepared. The slices were dried on a pathological tissue bleaching and drying instrument (PH 60 model, langyi) for 2h. Subsequently, the tissue sections were subjected to hydration with gradient alcohol (concentration from high to low, 95%, 85%, 70%), and the sections were rinsed with distilled water. Adding 3% hydrogen peroxide to act for 10 minutes, and removing endogenous peroxidase; three rinses of PBS for 5 minutes each; performing microwave repair by using antigen repair liquid, cooling to room temperature after repair, and rinsing with PBS for three times, each time for 5 minutes; blocking for 30 min at 37 ℃ with 1% bovine serum albumin; anti-type I collagen (1:200), anti-type IV collagen (1:200), anti-fibronectin antibody (1:200) and anti-elastin primary antibody were added dropwise, respectively, at 4℃overnight. Washing 3 times with 0.01M PBS, dripping goat anti-mouse secondary antibody, incubating for 30 minutes at 37 ℃, and washing 3 times with PBS for 5 minutes each time; DAB color development for 10 minutes under the condition of light shading, and washing the slices with distilled water; gradient alcohol dehydration (concentration from low to high, 80%, 95%, 100%), xylene transparency, neutral resin sealing. The staining results were observed under an optical microscope (ICX 41, short duration) and photographed, and the results are shown in FIGS. 1 to 4.
The results show that the decellularized biological net membrane prepared by the invention has a typical reticular structure and is expressed in a large amount of type I collagen, type IV collagen, fibronectin and elastin, which shows that the main protein component of the natural extracellular matrix is well reserved after the decellularized treatment and processing of the prepared decellularized biological net membrane. In addition, no obvious cellular components were seen in any of the histological stained sections, indicating that the present invention has a good decellularization effect (FIGS. 1-4).
Comparative example 1 DNAzyme method Decellularization treatment
Changing the decellularized liquid I into: weighing sodium dodecyl sulfate and DNase, dissolving in phosphate buffer, wherein the concentration of sodium dodecyl sulfate in the phosphate buffer is 2% by weight, the concentration of DNase in the phosphate buffer is 3000U/L, the pH is 7.3, filtering and sterilizing; the decellularized liquid II becomes: weighing sodium dodecyl sulfate and DNase, dissolving in phosphate buffer, wherein the concentration of sodium dodecyl sulfate in phosphate buffer is 1% by weight, the concentration of DNase in PBS is 1800U/L, the pH is 7.3, filtering and sterilizing; the decellularized fluid III became: weighing sodium dodecyl sulfate and DNase, dissolving in phosphate buffer, wherein the concentration of sodium dodecyl sulfate in phosphate buffer is 0.3% by weight, the concentration of DNase in PBS is 1200U/L, pH is 7.3, filtering and sterilizing. Other procedure referring to example 1, the large omentum of minipig origin was decellularized.
Comparative example 2 RNase-based decellularization treatment
Changing the decellularized liquid I into: weighing sodium dodecyl sulfate and RNase, dissolving in phosphate buffer, wherein the concentration of sodium dodecyl sulfate in the phosphate buffer is 2% by weight, the concentration of RNase in the phosphate buffer is 3000U/L, the pH is 7.3, filtering and sterilizing; the decellularized liquid II becomes: weighing sodium dodecyl sulfate and RNase, dissolving in phosphate buffer, wherein the concentration of sodium dodecyl sulfate in phosphate buffer is 1% by weight, the concentration of RNase in PBS is 1800U/L, the pH is 7.3, filtering and sterilizing; the decellularized fluid III became: weighing sodium dodecyl sulfate and RNase, dissolving in phosphate buffer, wherein the concentration of sodium dodecyl sulfate in phosphate buffer is 0.3% by weight, the concentration of DNase in PBS is 1200U/L, pH is 7.3, filtering and sterilizing. Other procedure referring to example 1, decellularized treatment was performed on the minipig-derived macroreticular membrane.
Example 3 DNA content test of decellularized omentum matrix
About 30mg of natural large omentum tissue is rapidly weighed, ground, and subjected to genome DNA extraction by using a blood/cell/tissue genome DNA extraction kit (TIANGEN, root biochemistry). About 30mg of DNA was weighed by the same method, and about 30mg of DNA was extracted from the prepared material by the DNase method, RNase method and decellularized biological omentum of the present invention (average value was taken by repeating 5 times each). DNA content was determined using a nucleic acid protein meter (SMARTSPEC PLUS, BI 0-RAD). As a result, FIG. 5 shows that the DNA content in the natural large omentum tissue was 335.78 to 26.10. Mu.g/g, that in the DNase method used in comparative example 1 was 25.38 to 2.45. Mu.g/g, that in the RNase method used in comparative example 2 was 21.94 to 2.78. Mu.g/g, and that in the decellularized omentum of example 1 of the present invention was 8.14 to 3.72. Mu.g/g.
As a result, the DNA content in the present invention was significantly reduced (25.38. Mu.g/g, 21.94. Mu.g/g and 8.14. Mu.g/g) in the decellularized biological omentum compared with the natural macroomentum tissue, and there was a substantial difference (p < 0.01), indicating that the cellular DNA components contained in the natural macroomentum tissue were substantially removed under the present invention's decellularization method treatment, and that the DNA removal effect of the present invention was significantly superior to that of the DNase method and the RNase method alone (the differences of each group had a statistical significance, p < 0.01).
The foregoing describes preferred embodiments of the present invention, but is not intended to limit the invention thereto. Modifications and variations to the embodiments disclosed herein may be made by those skilled in the art without departing from the scope and spirit of the invention.
Claims (5)
1. A method for preparing a decellularized biological omentum, comprising the following steps:
1) Taking fresh large omentum tissue, cleaning in phosphate buffer solution, and oscillating and soaking the cleaned tissue in degreasing solution for 12-36h with oscillation frequency of 150-250r/min;
2) Washing the fat-removed large omentum tissue in phosphate buffer solution, and oscillating and soaking in cell-free solution I for 6-10h at oscillation frequency of 100-200r/min;
3) Washing the large omentum tissue treated by the decellularized liquid I in phosphate buffer solution, and oscillating and soaking the large omentum tissue in the decellularized liquid II for 6-10h at an oscillation frequency of 100-200r/min;
4) Washing the large omentum tissue treated by the decellularized liquid II in phosphate buffer solution, and oscillating and soaking the large omentum tissue in the decellularized liquid III for 6-10h at an oscillation frequency of 100-200r/min;
5) Freeze-drying the large omentum tissue treated by the decellularized liquid III and then sterilizing;
wherein, the preparation steps of the decellularized liquid are as follows:
1) Decellularized liquid I: weighing sodium dodecyl sulfate, RNase and lipase, dissolving in phosphate buffer, wherein the concentration of sodium dodecyl sulfate in the phosphate buffer is 1.5-2.5% by weight, the concentration of RNase in the phosphate buffer is 2500-3500U/L, the concentration of lipase in the phosphate buffer is 1000-2000U/L, the pH is 7.2-7.4, filtering and sterilizing;
2) Decellularized liquid II: weighing sodium dodecyl sulfate, RNase and lipase, dissolving in phosphate buffer, wherein the concentration of sodium dodecyl sulfate in the phosphate buffer is 0.6-1.5% by weight, the concentration of RNase in the phosphate buffer is 1500-2000U/L, the concentration of lipase in the phosphate buffer is 500-1000U/L, the pH is 7.2-7.4, filtering and sterilizing;
3) Decellularized liquid III: weighing sodium dodecyl sulfate, RNase and lipase, dissolving in phosphate buffer, wherein the concentration of sodium dodecyl sulfate in the phosphate buffer is 0.1-0.5% by weight, the concentration of RNase in the phosphate buffer is 1000-1500U/L, the concentration of lipase in the phosphate buffer is 300-500U/L, the pH is 7.2-7.4, filtering and sterilizing.
2. The preparation method according to claim 1, wherein the degreasing solution is a mixed solvent of methanol and isopropanol.
3. The production method according to claim 2, wherein the volume ratio of the methanol to the isopropanol is 1-2: 1-2.
4. A decellularized biological omentum prepared by the method of any one of claims 1-3.
5. The decellularized biofilm of claim 4 having a DNA content of less than 12 μg/g.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410815430.2A CN118370871B (en) | 2024-06-24 | 2024-06-24 | Preparation method of decellularized biological omentum and decellularized biological omentum prepared by same |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410815430.2A CN118370871B (en) | 2024-06-24 | 2024-06-24 | Preparation method of decellularized biological omentum and decellularized biological omentum prepared by same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN118370871A CN118370871A (en) | 2024-07-23 |
| CN118370871B true CN118370871B (en) | 2024-09-06 |
Family
ID=91905865
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202410815430.2A Active CN118370871B (en) | 2024-06-24 | 2024-06-24 | Preparation method of decellularized biological omentum and decellularized biological omentum prepared by same |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN118370871B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104826165A (en) * | 2015-04-21 | 2015-08-12 | 北京帝康医药投资管理有限公司 | Preparation method of acellular bionet and acellular bionet prepared by preparation method |
| CN111110919A (en) * | 2019-12-30 | 2020-05-08 | 广东泓志生物科技有限公司 | Preparation method of omentum majus acellular matrix material and construction method of cartilage tissue |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090163990A1 (en) * | 2007-12-19 | 2009-06-25 | Chunlin Yang | Decellularized omentum matrix and uses thereof |
| CN104771788B (en) * | 2015-05-05 | 2017-08-25 | 北京帝康医药投资管理有限公司 | A kind of organization engineering skin and its construction method based on omentum majus acellular matrix |
| ES2684856B1 (en) * | 2015-12-30 | 2019-07-31 | Fundacion Tecnalia Res & Innovation | METHOD FOR PRODUCING A DECELULARIZED FABRIC MATRIX |
| CN115429937B (en) * | 2022-11-08 | 2023-04-28 | 圣至润合(北京)生物科技有限公司 | Soft tissue filling repair material and preparation method thereof |
-
2024
- 2024-06-24 CN CN202410815430.2A patent/CN118370871B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104826165A (en) * | 2015-04-21 | 2015-08-12 | 北京帝康医药投资管理有限公司 | Preparation method of acellular bionet and acellular bionet prepared by preparation method |
| CN111110919A (en) * | 2019-12-30 | 2020-05-08 | 广东泓志生物科技有限公司 | Preparation method of omentum majus acellular matrix material and construction method of cartilage tissue |
Also Published As
| Publication number | Publication date |
|---|---|
| CN118370871A (en) | 2024-07-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Choi et al. | Decellularized extracellular matrix derived from porcine adipose tissue as a xenogeneic biomaterial for tissue engineering | |
| WO2019206343A1 (en) | Biological valve material, preparation method therefor and application thereof, and crosslinking agent and application thereof | |
| CN109651627A (en) | Natural polymer crosslinking agent and its preparing the application in anticalcium biovalve | |
| CN108498869A (en) | Polyphenols crosslinking agent and its application in preparing anticalcium biovalve | |
| CN105126170A (en) | Acellular dermal matrix and preparing method of acellular dermal matrix | |
| CN112618799B (en) | Fish skin acellular dermal matrix and preparation method and application thereof | |
| KR20170142211A (en) | Implant and method of producing an implant by decellularising an tissue by perfusion under negative pressure | |
| CN104383601A (en) | Skeletal muscle acellular matrix biological patch and preparation method thereof | |
| CN105682697A (en) | Methods of removing alpha-galactose | |
| CN109364298A (en) | A kind of preparation method of acellular dermal matrix material | |
| CN115087470A (en) | Functionalized biological matrix material and preparation method and application thereof | |
| CN111084900A (en) | Preparation method and application of acellular fish skin matrix | |
| CN109529121A (en) | A kind of Acellular trachea matrix and preparation method thereof | |
| CN109675112B (en) | Preparation method of human-derived acellular dermal matrix | |
| CN113230454B (en) | Biological membrane capable of inducing bone regeneration and preparation method and application thereof | |
| KR102451565B1 (en) | Prehydrated-type acellular skin substitute and method of making the same | |
| CN118370871B (en) | Preparation method of decellularized biological omentum and decellularized biological omentum prepared by same | |
| CN105770991A (en) | Preparing method of biological source venous valve | |
| CN111518744A (en) | Liver acellular scaffold construction method based on irreversible electroporation technology | |
| CN110101909A (en) | A kind of preparation method for the de- cell biological amnion that properties of product are controllable | |
| CN116763990A (en) | Jellyfish cell removing material and preparation method and application thereof | |
| CN104826165A (en) | Preparation method of acellular bionet and acellular bionet prepared by preparation method | |
| Fedoniuk et al. | Morphological characteristics of acellular dermal matrix manufacturing | |
| Sokol et al. | Biocompatibility analysis of the decellularized bovine pericardium | |
| CN111939321B (en) | Preparation method of pig acellular dermal matrix skin substitute |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |